OncoMatch/Clinical Trials/NCT07647510
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
Is NCT07647510 recruiting? Yes, currently enrolling (Jul 2026). This Phase 3 trial studies Claseprubart for myasthenia gravis, generalized.
Treatment: Claseprubart — The purpose of this Phase 3 study is to demonstrate the efficacy, safety, and tolerability of claseprubart in participants with generalized myasthenia gravis (gMG).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Required: CHRNA1 antibody positive (positive)
Demographics
Prior therapy
Cannot have received: claseprubart (claseprubart, DNTH103)
Previous treatment with claseprubart (DNTH103) or participation in a clinical trial with claseprubart
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Cinical Study Site · Fayetteville, North Carolina
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07647510 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior claseprubart disqualifies patients from enrollment.
Does this trial require CHRNA1?
Yes, CHRNA1 antibody positive is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify